Status:
RECRUITING
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Lead Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...
Eligibility Criteria
Inclusion
- History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
- Measurable multiple myeloma (MM).
- Eastern Cooperative Oncology Group performance status of 0-1.
Exclusion
- Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
- Prior treatment with GPRC5D-targeting therapies.
- Note: Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
February 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT06121843
Start Date
February 22 2024
End Date
August 1 2028
Last Update
December 5 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
2
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona, United States, 85054
3
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
4
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224